Polymeric Nanosystems for Immunogenic Cell Death‐Based Cancer Immunotherapy

Citations Over TimeTop 21% of 2021 papers

Abstract

Immunotherapy has pointed out a scientific and promising direction for cancer treatment through the rouse of immunosurveillance and the decrease of possible side effects in recent years. In immunotherapy, immunogenic cancer cell death (ICD) plays a critical role in regulating anti-cancer immune system in vivo via the release of damage-associated molecular patterns. ICD can not only induce in situ cancer cells apoptosis, but also arouse the immune response against metastatic tumors, which is of great clinical significance to eradicate tumors. In cancer immunotherapy, polymer nanoparticles have drawn increasing attention as an important component of ICD-based immunotherapy attributing to their controllable size, excellent biocompatibility, promising ability of protecting cargo from surrounding environment, which delivers the antigens or immune inducers to antigen-presenting cells, and further triggers sinnvoll T cell response. In this review, the recent advances in the development of polymeric material-based nanosystems for ICD-mediated cancer immunotherapy are summarized. The mechanism of ICD and some current restrictions inhibiting the efficiency of immunotherapy and future prospects are also discussed.

Related Papers

• → Mechanisms of immunotherapy resistance: lessons from glioblastoma(2019)728 cited
• → Immunogenic cell death(2015)239 cited
• → A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy(2018)137 cited
• → Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment(2017)88 cited
• → Immunogenic Cell Death in Cancer(2023)2 cited